Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.17M | 7.20M | 7.29M | 7.07M | 6.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.68M | 16.67M | 16.01M | 13.27M | 11.28M |
| Operating Income | -16.68M | -16.67M | -16.01M | -13.27M | -11.28M |
| Income Before Tax | -12.77M | -16.44M | -14.28M | -13.71M | -14.69M |
| Income Tax Expenses | -3.20M | -3.07M | -2.67M | -2.27M | -1.83M |
| Earnings from Continuing Operations | -9.57 | -13.37 | -11.61 | -11.45 | -12.85 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.57M | -13.37M | -11.61M | -11.45M | -12.85M |
| EBIT | -16.68M | -16.67M | -16.01M | -13.27M | -11.28M |
| EBITDA | -16.67M | -16.67M | -16.01M | -13.27M | -11.27M |
| EPS Basic | -0.85 | -1.17 | -1.02 | -1.16 | -1.46 |
| Normalized Basic EPS | -0.70 | -0.90 | -0.78 | -0.86 | -0.90 |
| EPS Diluted | -0.85 | -1.17 | -1.02 | -1.16 | -1.46 |
| Normalized Diluted EPS | -0.70 | -0.90 | -0.78 | -0.86 | -0.90 |
| Average Basic Shares Outstanding | 47.77M | 45.43M | 45.43M | 41.48M | 37.99M |
| Average Diluted Shares Outstanding | 47.77M | 45.43M | 45.43M | 41.48M | 37.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |